Modified Nucleobases with Uniform H-Bonding for RNA Mismatch Discrimination

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing oligonucleotide molecules face challenges in achieving tight and sequence-specific binding to DNA or RNA targets, with limitations in enzymatic stability, cell permeability, and risk of nonspecific binding, particularly when targeting complex RNA structures like stem-loops.

Innovation Solution

Development of nucleobase-modified genetic recognition reagents with uniform hydrogen-bonding interactions, allowing for symmetrical binding and enhanced mismatch discrimination, enabling selective targeting of RNA secondary and tertiary structures.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional oligonucleotide molecules are used for binding to DNA or RNA targets, then binding can be achieved, but binding specificity and sequence-specific binding are limited

Engineering Contradiction:
Improvebinding specificityVSAvoidsequence-specific binding
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The patent modifies the chemical structure of nucleobases by changing parameters such as introducing fluorine atoms at specific positions (e.g., 5-fluorocytosine, 5-fluorouracil) and modifying hydrogen-bonding capabilities. These parameter changes in the molecular structure enable enhanced binding specificity and sequence-specific binding to target DNA or RNA sequences while reducing nonspecific interactions.

Inventive Principle:
Principle #35Parameter changes

2Measurement precision

If conventional oligonucleotide molecules are used for targeting RNA structures, then binding can occur, but discrimination against mismatches is insufficient

Engineering Contradiction:
Improvemismatch discriminationVSAvoidbinding specificity
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The patent introduces asymmetric modifications to nucleobases, such as fluorine substitution at specific positions in the nucleobase structure (e.g., 5-fluorocytosine, 5-fluorouracil). These asymmetric modifications create directional hydrogen-bonding interactions that provide enhanced discrimination against mismatched sequences while maintaining high binding specificity for the correct target sequence.

Inventive Principle:
Principle #4Asymmetry

3Reliability

If conventional oligonucleotide molecules are used for intracellular targeting, then binding to targets can be achieved, but cell permeability and enzymatic stability are limited

Engineering Contradiction:
Improvecell permeabilityVSAvoidenzymatic stability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent employs composite modifications where fluorinated nucleobases are incorporated into oligonucleotide molecules, creating a composite structure that combines the binding capabilities of conventional nucleic acids with the enhanced stability and permeability properties of fluorinated compounds. This composite approach improves both cell permeability and enzymatic stability while maintaining binding functionality.

Inventive Principle:
Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified nucleobases provide improved binding specificity and discrimination against mismatches, facilitating effective targeting of complex RNA structures while minimizing nonspecific interactions, thus enhancing therapeutic and diagnostic applications.

Implementation Method 1

modified nucleobases with uniform hydrogen-bonding interactions, allowing for symmetrical binding and enhanced mismatch discrimination

Methodology Applied
Scientific EffectHydrogen bonding:

Data Source

PatentEP3803398B1Modified nucleobases with uniform h-bonding interactions, homo- and hetero-basepair bias, and mismatch discrimination
Publication Date: 2025.08.13 CARNEGIE MELLON UNIV
  • EP3803398B1 patent drawingFigure 1(A)~1(C)
  • EP3803398B1 patent drawingFigure 2(A)~2(C)
  • EP3803398B1 patent drawingFigure 3(A)~3(B)

AI summary

Described herein are divalent nucleobases that each binds two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone, such as in a γ-peptide nucleic acid (γPNA). Also provided are genetic recognition reagents comprising one or more of the divalent nucleobases and a nucleic acid or nucleic acid analog backbone, such as a γPNA backbone. Uses for the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.